Ayala Pharmaceuticals Inc (ADXS)

[CATTDOGG12347]

We know AXAL works and works very well with an extremely low side effect profile. AXAL has been granted orphan designation for these indications which comes with 7 years of exclusivity( more money for a longer period of time). If AXAL for those indications was still available, we wouldn't see BMY partnering up for dual. They've obviously seen results that AXAL is garnering and want a piece of the pie in whatever form ADXS is willing to serve it up.
All of this sky is falling talk is just silly, no way you wouldn't be able to command some big dollars for an orphan product like AXAL in These indications.